Bradsaude stock
SAUD3.SASAOBradsaude S.A., HealthcareISIN BRSAUDACNOR9
80Score 80 out of 100, Strong
Price and trend
88 / 100
Price history
+33% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 14% above it.
Since March 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 51).
The price is 2.5% below its 52-week high. Largest decline in 20 years: 82% (February 2007 to April 2007).
Chart figures for advanced users
- SMA 50$2.68
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$2.54
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)51
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$1.89
- The lowest closing price of the last twelve months.
- Resistance$2.98
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Bradsaude S.A. belongs to the Medical (Healthcare Plans) industry (Brazil) and, with a market value of $8.49B, is number 9 of 12 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $435.56M (up 6.1% year on year) and earnings of $104.85M (up 8%).
- For fiscal 2026, analysts expect on average revenue of $9.65B (up 2,114.6%) and adjusted earnings per share of $0.25 (up 39.6%).
Show more
- MEQIRI Score 80 out of 100 (Strong): rank 22 of 714 in Healthcare, median 53.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- High return on capitalReturn on invested capital 53.6% in fiscal 2025, Healthcare sector median 9.1%.Profitability 70
- More cash than debtCash $52.74M, financial debt $3.75M.Stability 75
- High dividend yieldDividend yield 4.54%, Healthcare sector median 1.37%.Capital allocation 90
Weaknesses
None of our weakness checks flags anything. Crash risk is measured separately.
Its standout strengths are fundamentals and capital allocation.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 79 to 80.
Fundamentals are strong, with stable profits and strong cash generation.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk not measured
How well MEQIRI warnsFor stocks from Japan, China, Hong Kong, Taiwan, Korea, Canada, India and Brazil we only show crash risk once a separate backtest shows that it warns as well there as in the US and Europe.
Valuation
Valuation signal
not measuredClosing price of 11 Nov 2026, used by the daily score.
No fair value can be calculated for this stock, so the signal follows the valuation grade.
Valuation metrics
The share count in the financial statements does not match the market value (factor 0.2). Per-share figures such as the P/E and the fair value are therefore treated as not measured until the data match.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In fiscal 2025, revenue rose 6.1% on the prior year. Revenue has grown strongly since 2006, at around 14% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 35%, operating 30%, net 24%. Last 12 months: net 11%.
Debt & balance sheet
latest quarterThe balance sheet is solid, with low debt and comfortable interest coverage.
Earnings
- Next earnings
- 3 Mar 2027in 111 days
- Last reported
- 21 Oct 2026EPS reported $0.06 (expected $0.06)above expectations
Analyst estimates
Earnings estimates have barely changed since 25 Oct 2026.
- Earnings per share
- $0.25+0.7%
- Revenue
- $9.65B−0.7%
- Earnings per share
- $0.30+2.2%
- Revenue
- $11.13B−0.5%
MEQIRI has stored the estimates since 25 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
What happened at Bradsaude
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 80
- Sector median
- 53
Categories against the sector medianMedian of 714 companies
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Healthcare Plans)
The next larger and next smaller companies by market value
- CignaCI $79.43B66
- HumanaHUM $53.6B63
- CenteneCNC $34.89B54
- Molina HealthcareMOH $10.92B50
- Oscar HealthOSCR $9.93B71
- ProgynyPGNY $2.69B79
- Clover Health InvestmentsCLOV $2.64B52
- Alignment HealthcareALHC $1.61B41
ETFs that hold Bradsaude
Held by 12 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| Franklin FTSE Brazil UCITS ETF USDFLXB | 0.17% | 0.19% | €232.67M |
| WisdomTree Emerging Markets Equity Income UCITS ETF AccWTD8 | 0.12% | 0.46% | €256.08M |
| Avantis Emerging Markets Equity UCITS ETF USD AccAVEM | 0.06% | 0.35% | €277.45M |
Show 5 more
| Invesco FTSE All-World UCITS ETF USDFTWD | 0.04% | 0.15% | €4.75B |
| iShares Ageing Population UCITS ETF2B77 | 0.01% | 0.40% | €807M |
| Vanguard FTSE Emerging Markets UCITS ETF (USD) AccumulatingVFEA | 0.00% | 0.17% | €5.24B |
| Vanguard ESG Global All Cap UCITS ETF (USD) AccumulatingV3AA | 0.00% | 0.24% | €1.69B |
| Amundi Prime All Country World UCITS ETF AccWEBN | 0.00% | 0.07% | €8.65B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 11 Nov 2026 ($1 = R$5.5565)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 9 Oct 2026)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.